ArticleEuropean journal of gastroenterology & hepatology2026
Cardiovascular risk profiles in patients with primary sclerosing cholangitis.
Article in European journal of gastroenterology & hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic inflammation as seen in patients with primary sclerosing cholangitis (PSC) is linked to accelerated development and progression of atherosclerosis. This study aimed to assess atherosclerotic cardiovascular disease (ASCVD) risk and cardiovascular health (CVH) profiles in patients with PSC.
methodsThis cross-sectional study included PSC patients with and without concomitant inflammatory bowel disease (IBD), assessing cardiovascular risk with anthropometric measurements, serum samples, self-reported questionnaires, and medical chart review. The ideal CVH score was calculated according to the American Heart Association guidelines. Comparisons across groups were analyzed using χ 2 and Mann-Whitney U-test.
resultsNinety-eight patients with PSC were included [72% male; median age 49 years, interquartile range: 34-61 years], with 65% having concomitant IBD. PSC-IBD patients exhibited higher prevalence of obesity (15% vs 0%; P = 0.016), hypertension (35% vs 21%; P = 0.069), diabetes (9% vs 3%; P = 0.525), active smokers (10% vs 3%; P = 0.253) and metabolic syndrome (8% vs 3%; P = 0.363), and lower prevalence of hypercholesterolemia (30% vs 50%; P = 0.020). Nonideal CVH was more common among PSC-IBD (46% vs 22%; P = 0.045). Ten patients had a history of 16 ASCVD events. At time of these events, at 13/16 events patients had one or more traditional ASCVD risk factors of which 77% were modifiable.
conclusionOne-third of PSC patients exhibit nonideal CVH, particularly PSC-IBD patients. In this cohort, 10% had prior ASCVD with mostly modifiable risk factors at time of the event. These findings suggest that PSC patients might benefit from proactive ASCVD surveillance and risk management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.